{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-019747","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.605140+00:00","generated_at":"2026-05-25T15:57:53.054067+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin","bullets":["Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.","Abbott to assist with biostatistics, site selection, patient enrollment, and medical science liaison.","Cadrenal is regulatory sponsor; tecarfarin-related IP owned by Cadrenal, device-related IP by Abbott.","Phase 3 TECH-LVAD trial compares tecarfarin vs warfarin in HeartMate 3 LVAD patients with open-label extension.","No upfront or milestone payments disclosed; Cadrenal still pursuing additional funding partnerships for the study."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-019747","json":"https://secwatch.observer/filing/0001213900-25-019747.json","markdown":"https://secwatch.observer/filing/0001213900-25-019747.md","text":"https://secwatch.observer/filing/0001213900-25-019747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/0001213900-25-019747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025019747/ea0231833-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:57:53.054067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}